STOCK TITAN

Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company, has scheduled its fourth quarter and full year 2024 earnings release for Thursday, March 27, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day.

Key executives participating in the call include CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Investors can access the webcast through the company's investor relations website and join the conference call via domestic (844-481-2661) or international (412-317-0652) lines. A recording will be available on the company's website for those unable to attend the live event.

Co-Diagnostics (NASDAQ: CODX), un'azienda di diagnostica molecolare, ha programmato la pubblicazione dei risultati del quarto trimestre e dell'intero anno 2024 per giovedì 27 marzo 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 16:30 ET dello stesso giorno.

I principali dirigenti che parteciperanno alla chiamata includono il CEO Dwight Egan, il CFO Brian Brown e il Responsabile delle Relazioni con gli Investitori Andrew Benson. Gli investitori possono accedere alla trasmissione tramite il sito web delle relazioni con gli investitori dell'azienda e partecipare alla conferenza telefonica tramite numeri domestici (844-481-2661) o internazionali (412-317-0652). Una registrazione sarà disponibile sul sito web dell'azienda per coloro che non possono partecipare all'evento dal vivo.

Co-Diagnostics (NASDAQ: CODX), una empresa de diagnóstico molecular, ha programado la publicación de sus resultados del cuarto trimestre y del año completo 2024 para el jueves 27 de marzo de 2025, después del cierre del mercado. La empresa llevará a cabo una llamada de conferencia y una transmisión en vivo a las 4:30 p.m. ET el mismo día.

Los ejecutivos clave que participarán en la llamada incluyen al CEO Dwight Egan, al CFO Brian Brown y al Jefe de Relaciones con Inversores Andrew Benson. Los inversores pueden acceder a la transmisión a través del sitio web de relaciones con inversores de la empresa y unirse a la llamada de conferencia a través de líneas nacionales (844-481-2661) o internacionales (412-317-0652). Se dispondrá de una grabación en el sitio web de la empresa para aquellos que no puedan asistir al evento en vivo.

Co-Diagnostics (NASDAQ: CODX)는 분자 진단 회사로, 2025년 3월 27일 목요일에 2024년 4분기 및 연간 실적 발표를 시장 마감 후에 예정하고 있습니다. 회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다.

전화 회의에 참석하는 주요 경영진으로는 CEO 드와이트 이건, CFO 브라이언 브라운, 투자자 관계 책임자 앤드류 벤슨이 포함됩니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 국내(844-481-2661) 또는 국제(412-317-0652) 전화선을 통해 컨퍼런스 콜에 참여할 수 있습니다. 생중계에 참석할 수 없는 분들을 위해 회사 웹사이트에 녹화본이 제공될 예정입니다.

Co-Diagnostics (NASDAQ: CODX), une entreprise de diagnostics moléculaires, a prévu la publication de ses résultats du quatrième trimestre et de l'année complète 2024 pour jeudi 27 mars 2025, après la fermeture du marché. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30 ET le même jour.

Les principaux dirigeants participant à l'appel incluent le PDG Dwight Egan, le CFO Brian Brown et le Responsable des Relations Investisseurs Andrew Benson. Les investisseurs peuvent accéder au webinaire via le site web des relations investisseurs de l'entreprise et rejoindre la conférence téléphonique via des lignes domestiques (844-481-2661) ou internationales (412-317-0652). Un enregistrement sera disponible sur le site web de l'entreprise pour ceux qui ne peuvent pas assister à l'événement en direct.

Co-Diagnostics (NASDAQ: CODX), ein Unternehmen für molekulare Diagnostik, hat die Veröffentlichung der Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 für Donnerstag, den 27. März 2025, nach Börsenschluss angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten.

Zu den wichtigen Führungskräften, die an dem Anruf teilnehmen, gehören CEO Dwight Egan, CFO Brian Brown und der Leiter der Investor Relations Andrew Benson. Investoren können über die Investor-Relations-Website des Unternehmens auf den Webcast zugreifen und sich über nationale (844-481-2661) oder internationale (412-317-0652) Leitungen an der Telefonkonferenz beteiligen. Eine Aufzeichnung wird auf der Website des Unternehmens für diejenigen verfügbar sein, die nicht an der Live-Veranstaltung teilnehmen können.

Positive
  • None.
Negative
  • None.

SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts.  Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

The conference call and webcast will be available via:

Webcast: ir.codiagnostics.com on the Events & Webcasts page

Conference Call: 844-481-2661 (domestic) or 412-317-0652 (international)

If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-fourth-quarter-and-full-year-2024-earnings-release-date-and-webcast-302400872.html

SOURCE Co-Diagnostics

FAQ

When will Co-Diagnostics (CODX) release Q4 and full year 2024 earnings?

Co-Diagnostics will release Q4 and full year 2024 earnings on Thursday, March 27, 2025, after market close.

How can investors access CODX's Q4 2024 earnings call?

Investors can access the webcast at ir.codiagnostics.com or join via phone at 844-481-2661 (domestic) or 412-317-0652 (international).

What time is Co-Diagnostics (CODX) Q4 2024 earnings call?

The earnings call is scheduled for 4:30 p.m. ET on Thursday, March 27, 2025.

Which executives will participate in CODX's Q4 2024 earnings call?

CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson will participate in the call.
Co-Diagnostics Inc

NASDAQ:CODX

CODX Rankings

CODX Latest News

CODX Stock Data

15.97M
29.79M
6.7%
13.97%
0.82%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SALT LAKE CITY